

Virulence factors of *Candida* species isolated from patients with urinary tract infection and obstructive uropathy

Faris Q.B. Alenzi¹

ABSTRACT

Objective: Fungal urinary tract infections due to *Candida* have increased significantly in recent years. Our research objective was to study *Candida* species in urine samples of patients with urinary tract infections (UTIs) associated with obstructive uropathy and to investigate the virulence factors of the isolated *Candida*.

Methods: Patients were divided into two groups: **Group I (cases):** 50 patients with UTIs and obstructive uropathy. **Group II (control):** 50 patients with UTIs but with no functional or anatomical obstruction of their urinary tract. Clinical histories and physical examinations, together with laboratory investigations of urine samples were carried out in all patients in this study. Mid stream urine samples were examined microscopically and by fungal cell culture. The isolated *Candida* species were identified by analytical profile index (API). *Candida* Virulence factors were determined for the isolated *Candida*. The susceptibility to fluconazole was evaluated.

Results: This study revealed an overall isolation rate of 27% of *Candida* species among all patient groups. The rate was 36% in cases, and 18% in controls, a difference found to be statistically significant ($P < 0.05$). By API, *C. albicans* was detected in 44% of *Candida* species in cases, and in 33% in controls. While *C. glabrata* was detected in 28% of *Candida* species in cases, and in 22% in controls. *C. tropicalis* was detected in 17% of *Candida* species in cases, and in 22% in controls. Both *C. krusei* and *C. kyfr* were detected in 5.5% of *Candida* species in cases, and in 11% in controls. In terms of virulence factors the study showed that 11 out of 27 (40.5%) of *Candida* isolates were biofilm positive by tube adherence. Phospholipase activity was demonstrated in 12 out of 27 (44.5%) of *Candida* isolates. Secretory aspartic proteinase activity was demonstrated in 13 out of 27 (48%) of the *Candida* isolates.

Conclusion: *Candida* is an important cause of UTIs and obstructive uropathy is a major predisposing factor.

KEY WORDS: *Candida*, UTIs, Uropathy, Virulence.

doi: <http://dx.doi.org/10.12669/pjms.321.8559>

How to cite this:

Alenzi FQB. Virulence factors of *Candida* species isolated from patients with urinary tract infection and obstructive uropathy. *Pak J Med Sci.* 2016;32(1):143-146. doi: <http://dx.doi.org/10.12669/pjms.321.8559>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Faris Q.B. Alenzi,
Dept of Medical Laboratory Sciences,
College of Applied Medical Sciences,
Prince Sattam bin Abdulaziz University,
Al-Kharj, Saudi Arabia.

Correspondence:

Faris Q.B. Alenzi, Ph.D.
Professor of Immunology,
College of Applied Medical Sciences,
Prince Sattam bin Abdulaziz University,
Al-Kharj, Saudi Arabia.
E-mail: faris_alenzi@hotmail.com

- * Received for Publication: July 12, 2015
- * 1st Revision Received: July 23, 2015
- * 2nd Revision Received: October 19, 2015
- * Final Revision Accepted: October 25, 2015

INTRODUCTION

Community acquired urinary tract infections (UTIs) are a frequent problem worldwide and are caused by microbial invasion to different tissues of the urinary tract.¹ Fungi are a portion of the microbial population that may contribute as fungal uropathogens in UTIs. Over the last year, the incidence of fungal UTIs due to *Candida* has increased significantly.¹ The increased incidence of fungal infections in patients suffering from urinary tract infections associated with obstructive uropathy as well as the emergence of azole antifungal drug resistance justifies an immediate need to investigate

mechanisms of *Candida* species pathogenicity and their relationship to drug resistance.²

Secreted aspartyl proteinases (SAPs) are extracellular proteolytic enzymes that play a central role in *Candida* pathogenicity. SAPs carry out a number of specialized functions during the infection process, which facilitates their adhesion and tissue invasion.³ Phospholipases are another group of enzymes that contribute to the pathogenicity of *C. albicans* by damaging host-cell membranes, and thus facilitating fungal invasion of host tissues.⁴

There is a direct relationship between the adherence of *Candida* species and their ability to colonize the biomaterial. The species which are more adherent are those which are more virulent.² Therefore, rapid and reliable identification of *Candida* species and their virulence factors represents an important factor in routine clinical microbiology practice.

The aim of this work was to study different *Candida* species in urine samples from patients with urinary tract infections associated with obstructive uropathy, and to investigate the virulence factors of the isolated *Candida* species including; biofilm formation, the secreted aspartic proteinase and the extracellular phospholipase activity.

METHODS

This study was carried out on urine samples obtained from 100 patients attending primary health care centers, Arar, KSA. Patients were classified into two groups: Group I: included 50 patients with UTIs and obstructive uropathy. They comprised 18 males and 32 females. Their ages ranged from 15 to 58 years. Group II (controls): included 50 patients with UTIs and who had no functional or anatomical abnormality of urinary tract. They comprised 20 males and 30 females. Their age ranged from 14 to 53 years. This study was conducted at the Northern Borders region of Saudi Arabia (Arar) and other private centers in the region, Saudi Arabia between Jan-2013 to Jan-2015. Written informed consent and Research Ethics Committee approval were obtained in all cases.

Patients Received:

I. An assessment of their clinical history: Previous urologic problems, operation, terminal haematuria, dysuria and taking of antibiotics, or any other medications.

II. Clinical and radiological examination;

III. Laboratory investigations of urine samples: Including Mid-stream urine samples or catheterized urine samples were obtained under aseptic

conditions in sterile screw-capped wide mouth containers. Samples were subjected to microscopic examination and culture. Identification of *Candida* species by Gram-stain, Germ Tube test, subculture on chromID™ *Candida* Agar (CAN2): (bioMérieux) and biochemically by API *Candida* (bioMérieux).

Detection of virulence factors of *Candida*:

Biofilm Formation: Biofilm formation was carried out by tube adherence as by company instructions.

Phospholipase Activity: Assessment of phospholipase activity was carried out using Sabouraud egg yolk agar plate, in which the phospholipase activity was calculated as “the ratio of the diameter of the colony plus the precipitation zone around it to the diameter of the colony alone”.

Aspartic proteinase detection was carried out using bovine serum albumin (BSA) agar, Disc Diffusion Test was carried out using sterile swabs and plates of Mueller Hinton agar supplemented with 2% glucose.

Data Analysis: Data were analyzed using the SPSS software (Statistical Package for the Social Science) version 16.

RESULTS

The current study showed that 27% of the patients (27 out of 100) were *Candida* positive (Table-I). Also, the incidence of *Candida* infection in cases (group I) (obstructive uropathy) was found to be higher than that in controls (group II), i.e. 36% versus 18% (a difference which was statistically significant) (Table-I).

Candida species were identified by API *Candida*. In group I (cases), *C.albicans* was detected in 44% (8 out of 18), followed by *C.glabrata* in 28% (5 out of 18), and *C.tropicalis* in 17% of cases (3 out of 18). In group II controls, *C.albicans* was detected in 33% (3 out of 9), followed by *C. glabrata* and *C.tropicalis* in 22% in patients (2 out of 9). In both groups, *C.albicans* was detected in 41% of patients (11 out of 27), followed by *C. glabrata* in 26% (7 out of 27), and *C.tropicalis* in 19% in patients (5 out of 27). This study, 41% (11 out of 27) of *Candida* isolates were biofilm positive by tube adherence (Table-II).

Table-I: *Candida* isolates among studied groups.

Groups	<i>Candida</i> isolates		p- value
	No.	%	
Group-I, cases (n=50)	18	36	<0.05
Group-II , controls (n=50)	9	18	
Total (n =100)	27	27	

Table-II: *Candida albicans* & *Candida non albicans* among different groups by API.

Patient group	<i>Candida</i> isolates										Total
	<i>C.albicans</i>		<i>C.glabrata</i>		<i>C.tropicalis</i>		<i>C.krusei</i>		<i>C.kyfr</i>		
	No.	%	No.	%	No.	%	No.	%	No.	%	
Cases	8	44.4	5	27.7	3	16.6	1	5.5	1	5.5	18
Controls	3	33.3	2	22.2	2	22.2	1	11.1	1	11.1	9
Total	11	40.7	7	25.9	5	18.5	2	7.4	2	7.4	27

Table-III: Comparison between *C.albicans* & *C. non albicans* groups as regards to virulence factors.

	<i>C.albicans</i> (n=10)		<i>C. non albicans</i> (n=17)		p
	No	%	No	%	
Biofilm formation	2	20	9	53	<0.05
Phospholipase activity	5	50	7	41.	>0.05
Proteinase activity	7	70	6	35.	<0.05

Secretory aspartic proteinase activity was demonstrated in 13 out of 27 (48%) of *Candida* isolates. There were statistically significant differences in biofilm formation phospholipase activity and in proteinase activity between *C.albicans* and *C.non.albicans*. This study, *C.albicans* isolates recovered from urine demonstrated a lower percentage of biofilm positivity than other *Candida* species isolates (20% vs. 53%) (Table-III).

This study showed that 55% of *C.albicans*, 14% of *C.glabrata*, 60% of *C.tropicalis*, 50% of *C.krusei*, and 50% of *C.kyfr* were susceptible to fluconazole. In contrast, 27% of *C.albicans*, 71% of *C.glabrata*, 40% of *C.tropicalis*, 50% of *C.krusei*, and 50% *C.kyfr* were resistant to fluconazole (Table-IV).

DISCUSSION

All known *Candida* species are capable of causing UTIs. *C.albicans* was the most common isolated species. However, in many centers worldwide, non-*Candida albicans* species now predominate. The incidence of fungal infections is increasing because the number of immunocompromised

patients is increasing; also there is widespread use of broad-spectrum antibiotics and invasive devices or procedures.⁵ These results are in agreement with those of Din et al⁶ isolated *Candida* species from patients suffering from UTIs in 24% and 25%, respectively. In this study, API system has been used here for the characterization of *Candida* spp, which is only useful upto some extent. However, for research purpose, other alternative molecular methods can be consider as well.

Borst and Fluit⁷ in the Netherlands reported a prevalence rate of 24%, and Kobayashi et al⁸ in Brazil found a prevalence rate of 22%. A higher percentage in obstructive uropathy was also recorded and described by Frkiaer⁹ who found in a retrospective study of patients with genitourinary fungal infection, that obstructive uropathy was associated with 88% of cases.

These results are in agreement with those of Miller¹⁰ who detected *C.albicans* in 41% of cases, *C. glabrata* in 20%, and *C.tropicalis* in 17% by API system of *Candida* infection isolated from urine samples. Also higher results were also obtained by Alhussaini et al¹¹ who detected *C.albicans* in 54%, *C.glabrata* in 16%, and *C.tropicalis* in 6% of patients. Another study, conducted by Achkar and Fries¹² in 2010, found that in data collected from 10 medical centers in US, *C.albicans* was the commonest isolated from 52% of all *Candida* species, *C.glabrata* in 16%, and *C.tropicalis* in 8% of cases.

These findings are in agreement with those of Tortorano et al¹³ who have reported that the biofilm formation was observed in 39% of *Candida*

Table-IV: Susceptibility of isolates of *Candida* species as determined by the disc diffusion test to fluconazole.

<i>Candida</i> species	Susceptible			SDD*			Resistant		
	Zone diameter	No.	%	Zone diameter	No.	%	Zone diameter	No.	%
<i>C.albicans</i> (n=11)	22-32	6	54	18	2	10	10-12	3	27
<i>C.glabrata</i> (n=7)	28	1	14.3	16	1	14.3	1-12	5	71.4
<i>C.tropicalis</i> (n=5)	20-30	3	60	--	0	0	5-9	2	40
<i>C.krusei</i> (n=2)	35	1	50	--	0	0	5-12	1	50
<i>C. kyfr</i> (n=2)	29	1	50	--	0	0	12	1	50

Susceptible >19 mm, *Susceptible Dose Dependent (SDD), 15-18 mm, Resistant ≤ 14 mm.

isolates. Phospholipase activity in our study was demonstrated in 12 out of 27 (44%) of *Candida* isolates.

These results are in agreement with those Khun et al¹⁴ who reported that *C.albicans* isolates recovered from urine demonstrated lower percentage of biofilm positivity than other *Candida* species isolates. Our results also agree with that of Tsang et al¹⁵ who detected phospholipase activity in 84% of the *C. albican* isolates.

In conclusion, we herein report that *Candida* infection is an important cause of UTIs and obstructive uropathy is a major predisposing factor. The diagnostic and/or prognostic significance of these infections requires further study with a large cohort of patients.

ACKNOWLEDGEMENT

This project was supported by a research grant from the deanship of scientific research at Prince Sattam bin Abdulaziz University "REF 2014/01/2758". The author is highly thankful to Drs. Awwad Alanazi, Badi Alanazi for providing samples, and to Dr. Mohamed Al Rabea and Mr. Abdulmajeed Alanazi to providing some reagents and chemicals and to Prof. Richard Wyse for his critical reviewing of the manuscript.

REFERENCES

1. Andrade SS, Sader HS, Jones RN. Increased resistance to first line agents among bacterial pathogens isolated from urinary tract infections in Latin America, Time for local guidelines? Mem I Oswaldo Cruz. 2006;101(7):741-748.
2. Ellepola ANB, Morrison CJ. Squamous cell carcinoma of the bilharzial and non bilharzial urinary bladder: A review of etiological features, natural history and magement. J Clin Oncol. 2005;10:20-25.
3. Naglik JR, Scott J, Rahman D. Serum and saliva antibodies do not inhibit *Candida albicans* SAP2 proteinase activity using a BSA hydrolysis assay. Med Mycol. 2005;43:73-77.
4. Birinci A, Cihan CC, Bilgin K. Investigation of phospholipase activity of *Candida* species isolated from different clinical samples. Microbiol Bul. 2006;39:205-209.
5. Pfaller MA, Hazen KC, Messer SA. Comparison of results of fluconazole disk diffusion testing for *Candida* species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. J Clin Microbiol. 2004;42:3607-3612.
6. Saad El- Din S, Aboul Fad L, El- Baz A. Catheter related funguria: Identification and antifungal susceptibility. Egypt J Med Microbiol. 2002;11:557-568.
7. Borst A, Fluit AC. high levels of hydrolytic enzymes secreted by *Candida albicans* isolates involved in respiratory infections. J Med Microbiol. 2003;52:971-974.
8. Kobayashi CC, De Fernandes OF, Miranda KC. Candiduria in hospital patients: A study prospective. Mycopathologia. 2004;158:49-52.
9. Frokiaer J, Zeidel ML. Urinary tract obstruction. In: Brenner BM, ed. Brenner and Rector's The Kidney. 8th ed. Philadelphia, Pa ; Saunders Elsevier; 2007: chap 35 (BOOK).
10. Miller JM. Evaluating biochemical identification systems. J Clin Microbiol. 2005;29:1559-1561.
11. Alhussaini MS, El-Tahtawi NF, Moharam A. Phenotypic and molecular characterization of *Candida* species in urine samples from renal failure patients. J Clin Med. 2013;2:14-25.
12. Achkar JM, Fries BC. *Candida* infections of the genitourinary tract. Clin Microbiol Rev. 2010;23:253-73.
13. Tortorano AM, Prigitano A, Biragizi E. The european confederation of medical mycology (ECMM) survey of *Candidaemia* in Italy: In vitro susceptibility of 375 *Candida albicans* isolates and biofilm production. J Antimicrob Chemother. 2005;56:777-779.
14. Khun DM, Chandr J, Mukherjee PK. A comparison of biofilm formed by *C. albicans* and *C. Parapsilosis* on bioprosthetic surfaces. Infect Immuno. 2008;70:878-888.
15. Tsang CSP, Chu FCS, Leung WK. Phospholipase, proteinase and haemolytic activities of *Candida albicans* isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol. 2007;56:1393-1398.